AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
FRA Edition 
GER Edition 
ESP Edition 
ITA Edition 
NLD Edition 
PRT Edition 
SWE Edition 
GRC Edition 
IND Edition 
POL Edition 
BRA Edition 
ZAF Edition 
RUS Edition 
CHN Edition 
UAE Edition 
⚠
✓
Adial Pharmaceuticals Inc (NASDAQ:ADIL)
0.2342 USD
-0.091 27.961%| Previous Close (in USD) | 0.3251 |
|---|---|
| Change | -0.091 27.961% |
| 52 W H/L (in USD) | 4.170/0.765 |
| EBITDA (in USD) | -7.273M |
| PE Ratio | -- |
| Volume | 5289634 |
| Diluted Eps TTM | -2.94 |
| Total Assets (in USD) | 4.737M |
|---|---|
| Total Liabilities (in USD) | 0.654M |
| Revenue TTM (in USD) | -- |
| Cash (in USD) | 2.827M |
| Market Cap (in USD) | 7.559 M |
| Revenue Per Share TTM | -- |
| Gross Profit TTM (in USD) | -- |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
Adial Pharmaceuticals Inc
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Glen Allen, Virginia.
Employees: 4
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Mr. Cary John Claiborne MBA | CEO, Pres & Director | 1961 |
| 2. | Mr. Joseph A. M. Truluck M.B.A., MBA | CFO, Treasurer & Sec. | 1978 |
| 3. | Dr. Bankole A. Johnson DSc, FRCPsych, M.D., M.Phil, Ph.D. | Founder & Chief Medical Officer | 1960 |
| 4. | Mr. John R. Martin J.D. | Gen. Counsel | NA |
| 5. | Mr. Alex Lugovoy | Chief Bus. Officer | NA |
| 6. | Dr. Jack W. Reich Ph.D. | Head of Regulatory | 1949 |
| 7. | Mr. Mark H. Peikin | Chief Strategy Officer & Chief Devel. Officer | NA |
| 8. | Mr. Lawrence Goldman CPA | Controller | 1956 |
| 9. | Ms. Catherine Fratila | Controller | NA |
| 10. | Mr. Cary John Claiborne MBA | CEO, President & Director | 1961 |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-2.380 3.090% | 75.51 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-3.160 4.035% | 77.64 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
-2.280 0.506% | 449.43 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
-3.845 0.736% | 519.27 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -12.732M | -19.517M | -10.893M | -8.591M | -11.631M |
| Minority Interest | - | - | - | - | - |
| Net Income | -12.731M | -19.423M | -10.86M | -8.591M | -11.631M |
| Selling General Administrative | 9.14M | 9.345M | 5.075M | 4.279M | 6.619M |
| Gross Profit | - | - | - | - | 0M |
| Reconciled Depreciation | 0.061M | 0.055M | 0.001M | 0.001M | 0.001M |
| Ebit | -13.317M | -19.289M | -10.928M | -8.245M | -6.98M |
| Ebitda | -13.779M | -15.855M | -10.927M | -8.149M | -6.979M |
| Depreciation And Amortization | -0.461M | 3.434M | 0.001M | 0.096M | 0.001M |
| Operating Income | -13.317M | -19.289M | -10.928M | -8.245M | -6.987M |
| Other Operating Expenses | 13.317M | 17.74M | 10.928M | 8.245M | 6.987M |
| Interest Expense | 0.585M | 3.607M | 0M | 0M | 1.167M |
| Tax Provision | -0.001M | -0.094M | 0M | 0M | 0M |
| Interest Income | 0.063M | 0.007M | 0.032M | 0.095M | 0.007M |
| Net Interest Income | 0.063M | 0.007M | 0.032M | 0.095M | -1.16M |
| Income Tax Expense | -0.001M | -0.094M | -0.032M | 0.442M | -3.477M |
| Total Revenue | 0M | 0M | 0M | 0M | 0M |
| Total Operating Expenses | 13.317M | 17.74M | 10.928M | 8.245M | 6.987M |
| Cost Of Revenue | - | - | - | - | 0M |
| Total Other Income Expense Net | 0.585M | -0.229M | 0.035M | -0.347M | -3.485M |
| Net Income From Continuing Ops | -12.731M | -19.423M | -10.893M | -8.591M | -11.631M |
| Net Income Applicable To Common Shares | - | -19.423M | -10.893M | -8.591M | -11.631M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 4.737M | 5.733M | 7.475M | 5.491M | 7.68M |
| Intangible Assets | 0.004M | 0.459M | 0.46M | 0.006M | 0.006M |
| Other Current Assets | 0.372M | 0.349M | 0.39M | 0.502M | 0.359M |
| Total Liab | 0.654M | 2.456M | 3.967M | 1.505M | 0.539M |
| Total Stockholder Equity | 4.084M | 3.276M | 3.508M | 3.986M | 7.141M |
| Other Current Liab | 0.526M | 1.34M | 0.01M | 0.857M | 0.349M |
| Common Stock | 0.002M | 0.027M | 0.021M | 0.014M | 0.01M |
| Capital Stock | - | 0.027M | 0.021M | 0.014M | 0.01M |
| Retained Earnings | -68.798M | -63.675M | -50.943M | -31.52M | -20.627M |
| Good Will | - | 0.249M | 0.249M | - | - |
| Other Assets | - | - | - | 0.35M | - |
| Cash | 2.827M | 4.002M | 6.062M | 4.401M | 6.777M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 0.653M | 1.791M | 2.722M | 1.505M | 0.539M |
| Current Deferred Revenue | - | - | 2.377M | - | - |
| Net Debt | -2.827M | -3.794M | -5.805M | -4.401M | -6.777M |
| Short Term Debt | - | 0.057M | 0.05M | - | - |
| Short Long Term Debt | - | - | - | - | - |
| Short Long Term Debt Total | - | 0.207M | 0.257M | - | - |
| Other Stockholder Equity | 72.88M | 66.924M | 54.43M | 35.491M | 27.757M |
| Property Plant Equipment | - | - | 0.304M | - | - |
| Total Current Assets | 3.199M | 4.78M | 6.462M | 5.136M | 7.673M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | - | - | - | - | - |
| Net Receivables | - | - | - | - | - |
| Long Term Debt | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Accounts Payable | 0.127M | 0.394M | 0.286M | 0.649M | 0.19M |
| Accumulated Other Comprehensive Income | - | - | - | - | - |
| Non Currrent Assets Other | 1.534M | 0.649M | 0.701M | 0.35M | 0.006M |
| Non Current Assets Total | 1.538M | 0.953M | 1.013M | 0.356M | 0.006M |
| Capital Lease Obligations | - | 0.207M | 0.257M | - | - |
| Long Term Debt Total | - | - | - | - | - |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 0M | -0.034M | -0.35M | - | 0M |
| Total Cashflows From Investing Activities | - | -0.034M | -0.35M | -0.35M | -0.35M |
| Total Cash From Financing Activities | 9.126M | 13.645M | 5.607M | 9.247M | 6.349M |
| Net Income | -12.731M | -19.423M | -10.893M | -8.591M | -11.631M |
| Change In Cash | -2.06M | 1.661M | -2.376M | 2.908M | 3.851M |
| Begin Period Cash Flow | 6.062M | 4.401M | 6.777M | 3.869M | 0.018M |
| End Period Cash Flow | 4.002M | 6.062M | 4.401M | 6.777M | 3.869M |
| Total Cash From Operating Activities | -11.186M | -11.949M | -7.633M | -6.339M | -2.498M |
| Depreciation | 0.061M | 0.055M | 0.001M | 0.001M | 0.001M |
| Other Cashflows From Investing Activities | - | - | -0.35M | -0.35M | -0.35M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | - | - | - | - | - |
| Sale Purchase Of Stock | - | - | 5.607M | 9.247M | 6.424M |
| Other Cashflows From Financing Activities | 0.002M | 1.894M | 0.45M | 1.051M | 0.841M |
| Capital Expenditures | 0M | 0.065M | 0.065M | 0.065M | 0.065M |
| Change In Working Capital | -1.367M | 1.464M | 1.245M | 0.208M | -0.849M |
| Other Non Cash Items | -0.522M | 1.808M | 4.749M | 0.442M | 1.129M |
| Free Cash Flow | -11.186M | -12.014M | -7.633M | -6.339M | -2.498M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Fidelity Extended Market Index | 7 months ago | 35139 |
| 2. | BlackRock Extended Equity Market K | 8 months ago | 17572 |
| 3. | Vanguard Institutional Extnd Mkt Idx Tr | 7 months ago | 9359 |
| 4. | Fidelity Series Total Market Index | 7 months ago | 9158 |
| 5. | Fidelity Total Market Index | 7 months ago | 7754 |
| 6. | Extended Equity Market Fund M | 8 months ago | 2230 |
| 7. | Spartan Extended Market Index Pool E | 7 months ago | 787 |
| 8. | Northern Trust Extended Eq Market Idx | 8 months ago | 598 |
| 9. | NT Ext Equity Mkt Idx Fd - L | 8 months ago | 598 |
| 10. | NT Ext Equity Mkt Idx Fd - NL | 8 months ago | 520 |
| 11. | NT Ext Equity Mkt Idx Fd - DC - NL - T2 | 8 months ago | 419 |
| 12. | State St US Extended Mkt Indx NL Cl C | 6 months ago | 308 |
| 13. | SSgA U.S. Total Market Index Strategy | 11 months ago | 126 |
| 14. | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 8 months ago | 92 |
| 15. | State St US Ttl Mkt Indx SL Cl I | 7 months ago | 88 |
| 16. | Northern Trust Wilshire 5000 | 8 months ago | 52 |
| 17. | BlackRock Extended Mkt Composite | 1 year ago | 31 |
| 18. | BlackRock Extended Equity Market K | 1 year ago | 27 |
| 19. | NT Ext Eq Mkt Indx Fd DC Lending Tier 5 | 1 year ago | 24 |
| 20. | Extended Equity Market Fund M | 1 year ago | 3 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Manchester Capital Management LLC | 8 months ago | 48097 |
| 2. | Geode Capital Management, LLC | 8 months ago | 45466 |
| 3. | Citadel Advisors Llc | 8 months ago | 33270 |
| 4. | BlackRock Inc | 11 months ago | 27770 |
| 5. | TWO SIGMA SECURITIES, LLC | 8 months ago | 27115 |
| 6. | UBS Group AG | 8 months ago | 4404 |
| 7. | Tower Research Capital LLC | 8 months ago | 3943 |
| 8. | 1620 Investment Advisors Inc | 8 months ago | 3600 |
| 9. | Morgan Stanley - Brokerage Accounts | 8 months ago | 309 |
| 10. | Bank of America Corp | 8 months ago | 52 |
| 11. | Benjamin F. Edwards & Company, Llc | 11 months ago | 40 |
| 12. | Abound Wealth Management | 8 months ago | 27 |
| 13. | Royal Bank of Canada | 11 months ago | 19 |
| 14. | Wells Fargo & Co | 11 months ago | 0 |
| 15. | Headlands Technologies LLC | 11 months ago | 0 |
| 16. | Renaissance Technologies Corp | 8 months ago | 0 |
| 17. | Qube Research & Technologies | 8 months ago | 0 |
| 18. | Virtu Financial LLC | 11 months ago | 0 |
| 19. | Advisor Group Holdings, Inc. | 11 months ago | 0 |
| 20. | HRT FINANCIAL LLC | 8 months ago | 0 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...